Elutia (ELUT) to Release Earnings on Wednesday

Elutia (NASDAQ:ELUT) will likely be releasing its Q4 2025 results after the market closes on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $3.30 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 5:00 PM ET.

Elutia Price Performance

Shares of ELUT opened at $1.17 on Tuesday. The firm has a market capitalization of $49.96 million, a price-to-earnings ratio of -1.27 and a beta of 0.65. Elutia has a 1-year low of $0.50 and a 1-year high of $3.46. The company has a 50-day moving average of $0.95 and a 200 day moving average of $0.99.

Insider Activity

In other Elutia news, CFO Matthew Ferguson acquired 60,000 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was bought at an average cost of $0.53 per share, with a total value of $31,800.00. Following the completion of the purchase, the chief financial officer directly owned 447,110 shares in the company, valued at $236,968.30. The trade was a 15.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin Rakin bought 70,000 shares of the company’s stock in a transaction on Friday, January 30th. The shares were acquired at an average price of $1.06 per share, for a total transaction of $74,200.00. Following the completion of the acquisition, the director owned 196,120 shares in the company, valued at $207,887.20. This represents a 55.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 255,500 shares of company stock valued at $189,605 over the last 90 days. 27.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Elutia

Institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. bought a new position in Elutia in the third quarter worth approximately $1,221,000. XTX Topco Ltd purchased a new position in shares of Elutia in the 4th quarter valued at $71,000. Renaissance Technologies LLC increased its holdings in shares of Elutia by 64.7% in the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after acquiring an additional 40,123 shares during the period. Citadel Advisors LLC bought a new position in shares of Elutia in the 3rd quarter worth $50,000. Finally, Virtu Financial LLC bought a new position in shares of Elutia in the 3rd quarter worth $26,000. 74.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elutia in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Elutia presently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.